For decades, the prevailing theory was that amyloid plaques caused Alzheimer's. However, clinical trials for drugs that successfully clear these plaques, like Aducanumab, have shown minimal to no cognitive benefit, forcing a re-evaluation of this dogma.
With amyloid's role demoted to an early initiator, tau tangles are now seen as a primary driver of neurodegeneration and cognitive symptoms. The biomarker p-tau217 is the single most predictive marker for the onset of clinical Alzheimer's, making tau-targeting therapies a key area of focus.
Babylon Bio's model involves acquiring promising but deprioritized assets from large pharmaceutical companies. This "pharma arbitrage" strategy, exemplified by the $11.6B Pfizer-Biohaven deal, allows a smaller, focused company to de-risk and advance drugs more efficiently.
The company is using fine-tuned AI models, in collaboration with OpenAI, to analyze vast scientific literature and predict clinical trial success. This approach aims to overcome human cognitive limitations and identify non-obvious therapeutic connections.
The discussion emphasizes that in long-cycle, high-risk ventures, team composition is paramount. The strategy is to filter for individuals with extreme passion and dedication, believing that burnout stems from a lack of agency, not overwork.
Keep pulling the thread on Sacha Schermerhorn.